Hims & Hers Health, Inc. (NYSE:HIMS) Short Interest Up 20.3% in May

Hims & Hers Health, Inc. (NYSE:HIMSGet Free Report) was the recipient of a significant growth in short interest in May. As of May 15th, there was short interest totalling 22,130,000 shares, a growth of 20.3% from the April 30th total of 18,390,000 shares. Based on an average trading volume of 8,300,000 shares, the days-to-cover ratio is presently 2.7 days. Currently, 14.7% of the shares of the stock are short sold.

Analyst Ratings Changes

Several research analysts have commented on the stock. Seaport Res Ptn restated a “buy” rating on shares of Hims & Hers Health in a report on Friday, April 26th. Truist Financial lifted their price target on Hims & Hers Health from $10.00 to $13.00 and gave the company a “hold” rating in a research report on Tuesday, February 27th. Jefferies Financial Group reissued a “hold” rating and set a $15.00 price objective (down previously from $17.00) on shares of Hims & Hers Health in a research report on Tuesday, April 16th. Citigroup downgraded shares of Hims & Hers Health from a “buy” rating to a “neutral” rating and upped their target price for the stock from $16.00 to $20.00 in a research report on Wednesday, May 22nd. Finally, SVB Leerink initiated coverage on shares of Hims & Hers Health in a research report on Monday, February 26th. They set a “market perform” rating and a $10.00 price target for the company. Seven investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, Hims & Hers Health presently has an average rating of “Moderate Buy” and an average price target of $15.69.

View Our Latest Stock Report on HIMS

Hims & Hers Health Price Performance

Hims & Hers Health stock opened at $20.36 on Friday. Hims & Hers Health has a one year low of $5.65 and a one year high of $21.44. The business’s fifty day moving average is $14.39 and its 200 day moving average is $11.45. The stock has a market capitalization of $4.37 billion, a PE ratio of -2,036.00 and a beta of 0.97.

Hims & Hers Health (NYSE:HIMSGet Free Report) last announced its quarterly earnings results on Monday, May 6th. The company reported $0.05 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.02 by $0.03. Hims & Hers Health had a negative net margin of 0.24% and a negative return on equity of 0.70%. The firm had revenue of $278.20 million for the quarter, compared to the consensus estimate of $270.37 million. During the same quarter last year, the firm posted ($0.05) EPS. The business’s quarterly revenue was up 45.8% compared to the same quarter last year. As a group, sell-side analysts expect that Hims & Hers Health will post 0.18 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, insider Soleil Boughton sold 2,502 shares of Hims & Hers Health stock in a transaction on Tuesday, May 28th. The shares were sold at an average price of $17.33, for a total value of $43,359.66. Following the transaction, the insider now owns 156,855 shares in the company, valued at approximately $2,718,297.15. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other Hims & Hers Health news, insider Soleil Boughton sold 2,502 shares of the business’s stock in a transaction that occurred on Tuesday, May 28th. The stock was sold at an average price of $17.33, for a total value of $43,359.66. Following the completion of the sale, the insider now owns 156,855 shares in the company, valued at $2,718,297.15. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Melissa Baird sold 11,751 shares of Hims & Hers Health stock in a transaction on Wednesday, March 6th. The stock was sold at an average price of $13.99, for a total transaction of $164,396.49. Following the completion of the transaction, the chief operating officer now directly owns 507,465 shares in the company, valued at $7,099,435.35. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 594,308 shares of company stock valued at $8,464,914. 17.71% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Hims & Hers Health

A number of large investors have recently added to or reduced their stakes in HIMS. Victory Capital Management Inc. boosted its stake in shares of Hims & Hers Health by 23.0% in the 4th quarter. Victory Capital Management Inc. now owns 18,348 shares of the company’s stock worth $163,000 after buying an additional 3,429 shares during the last quarter. Graham Capital Management L.P. boosted its position in Hims & Hers Health by 39.4% in the third quarter. Graham Capital Management L.P. now owns 340,338 shares of the company’s stock worth $2,141,000 after purchasing an additional 96,277 shares during the last quarter. Forerunner Ventures Management LLC bought a new stake in shares of Hims & Hers Health during the 4th quarter valued at about $86,836,000. Swiss National Bank increased its position in shares of Hims & Hers Health by 9.2% during the 3rd quarter. Swiss National Bank now owns 309,200 shares of the company’s stock valued at $1,945,000 after purchasing an additional 26,100 shares during the last quarter. Finally, Vanguard Group Inc. increased its position in shares of Hims & Hers Health by 3.1% during the 3rd quarter. Vanguard Group Inc. now owns 14,126,744 shares of the company’s stock valued at $88,857,000 after purchasing an additional 428,671 shares during the last quarter. Institutional investors own 63.52% of the company’s stock.

About Hims & Hers Health

(Get Free Report)

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.

Further Reading

Receive News & Ratings for Hims & Hers Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hims & Hers Health and related companies with MarketBeat.com's FREE daily email newsletter.